<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-35395" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Glucosamine Sulfate</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Williams</surname>
            <given-names>Caroline</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ampat</surname>
            <given-names>George</given-names>
          </name>
          <aff>University of Liverpool</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Caroline Williams declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>George Ampat declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-35395.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Glucosamine sulfate is an oral supplement used in the management and treatment of osteoarthritis. This activity outlines the indications, hypothesized action, and contraindications for glucosamine sulfate as a valuable agent in managing osteoarthritis. This activity will highlight the hypothesized mechanism of action, adverse event profile, suggested dosing, monitoring for relevant interactions, and other key elements of glucosamine sulfate supplementation in the clinical setting pertinent for members of an interprofessional team managing the care of patients with osteoarthritis.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the treatment considerations for osteoarthritic patients requesting to add glucosamine sulfate supplements to their treatment strategy.</p></list-item><list-item><p>Describe the management considerations for patients taking glucosamine sulfate supplements.</p></list-item><list-item><p>Summarize the risks associated with initiating glucosamine sulfate supplementation and related key patient counseling points.</p></list-item><list-item><p>Explain the importance of collaboration and communication amongst the interprofessional team to ensure the appropriate screening of patients requesting glucosamine sulfate supplements as a part of their osteoarthritis management to improve patient outcomes by identifying contraindications and thus decreasing adverse events.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=35395&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=35395">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-35395.s2" sec-type="Indications">
        <title>Indications</title>
        <p>There is currently no FDA-approved indication for glucosamine sulfate, despite its popularity as a supplement in the treatment of osteoarthritis.</p>
        <p>Osteoarthritis (OA), a common degenerative joint disease affecting 240 million worldwide,&#x000a0;is a progressive condition most frequently affecting the larger weight-bearing joints of the body.<xref ref-type="bibr" rid="article-35395.r1">[1]</xref> Despite the prevalence of this debilitating disorder, there persists a lack of OA-targeted pharmacotherapeutics. Available options largely focus on decreasing OA-associated pain, with NSAIDs and other analgesics being the most commonly used.<xref ref-type="bibr" rid="article-35395.r2">[2]</xref>&#x000a0;Supplements theorized to support joint health, such as glucosamine sulfate formulations, have maintained popularity as adjunct therapies in osteoarthritis management.<xref ref-type="bibr" rid="article-35395.r3">[3]</xref>&#x000a0;Literature to date has not proven glucosamine sulfate supplements to slow disease progression or effectively decrease OA-associated pain, with randomized control studies showing conflicting results.<xref ref-type="bibr" rid="article-35395.r4">[4]</xref><xref ref-type="bibr" rid="article-35395.r5">[5]</xref></p>
        <p>Although in vitro studies have demonstrated that glucosamine formulations significantly downregulate and upregulate catabolic and anabolic processes, respectively, human clinical trials completed to date have been unable to demonstrate these effects in vivo effectively. Although various studies have attempted to evaluate the effectiveness of glucosamine sulfate as a therapeutic agent in the treatment of OA, the majority of these have been of poor quality and/or at high risk of sponsorship bias. Most studies showing symptomatic improvement secondary to glucosamine sulfate treatment were&#x000a0;generally of lower quality and small sample size, making it difficult to draw conclusions. The remaining, larger studies hold a high probability of bias, as the majority appears to have been sponsored by corporations manufacturing these formulations. Moreover, the heterogeneity between studies examining the capacity of oral glucosamine sulfate as an OA therapy is prohibitive of pooling data and validating conclusions. The verdict regarding the use of the supplement as an adjunct osteoarthritis therapy remains unclear.<xref ref-type="bibr" rid="article-35395.r6">[6]</xref>&#x000a0;</p>
        <p>As a result, there are no current guidelines on its use for osteoarthritis for the majority of joints due to lack of definitive evidence except for the knee; The American Academy of Orthopaedic Surgeons (AAOS) recommends against the use of glucosamine sulfate as a treatment for knee arthritis specifically following AHRQ report presents a high-quality systematic review of level I evidence covering the best available evidence and does not support the prescribing of glucosamine and/or chondroitin symptomatic OA of the knee.<xref ref-type="bibr" rid="article-35395.r7">[7]</xref></p>
        <p>Other possible indications for glucosamine sulfate include temporomandibular joint disorder and rheumatoid arthritis. However, similar to osteoarthritis, there is no evidence to date supporting the effectiveness of glucosamine sulfate as an agent for symptomatic relief or as a modifier of disease progression.<xref ref-type="bibr" rid="article-35395.r8">[8]</xref></p>
      </sec>
      <sec id="article-35395.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Researchers have not identified the mechanisms of action for glucosamine sulfate in vivo, despite being the focus of various studies. However, what does seem certain is that glucosamine sulfate shows notable bioavailability following oral administration and decreased clearance compared to alternative formulations of glucosamine supplements such as glucosamine hydrochloride.<xref ref-type="bibr" rid="article-35395.r9">[9]</xref>&#x000a0;In light of this known bioavailability, the theorized therapeutic benefits of orally administered, exogenous glucosamine sulfate supplements are based on the hypothesized functions of endogenous glucosamine.&#x000a0;Glucosamine is a naturally occurring amino sugar that serves as a fundamental building block of glycosaminoglycans, one of the structural components found in cartilage and other connective tissues. Glycosaminoglycans are key contributors to cartilaginous properties, such as elasticity, strength, and flexibility.<xref ref-type="bibr" rid="article-35395.r10">[10]</xref><xref ref-type="bibr" rid="article-35395.r11">[11]</xref></p>
        <p>The theorized mechanism of action of glucosamine, and thus, glucosamine sulfate, is largely based on in vitro studies analyzing its interaction with cell types found in the joint space.&#x000a0;The proposed mechanism of action of glucosamine sulfate is thus two-fold. First, the theory is that glucosamine sulfate stimulates the synthesis of glycosaminoglycans and augments type II collagen expression in chondrocytes. Secondly, it is believed that glucosamine sulfate prevents glycosaminoglycan and collagen degradation by down-regulating the production of inflammatory cytokines via decreased prostaglandin E2 synthesis, inhibition of nuclear factor kappa B (NFkB), and decreased expression of catabolic enzymes such as metalloproteinases (MPs).<xref ref-type="bibr" rid="article-35395.r11">[11]</xref><xref ref-type="bibr" rid="article-35395.r12">[12]</xref></p>
        <p>The mechanism of action of glucosamine sulfate is often discussed in reference to the derangements in joint pathophysiology seen in osteoarthritis. Osteoarthritis characteristically manifests an imbalance between the synthesis of structural proteins of articular cartilage such as proteoglycans and collagen and their degradation by matrix metalloproteinases (MMPs).&#x000a0; In patients affected by this disease, chondrocytes can become activated to release pro-inflammatory cytokines due to environmental stress.<xref ref-type="bibr" rid="article-35395.r13">[13]</xref> Due to these postulated effects on cartilage turnover processes, the hypothesis is that glucosamine sulfate may serve a role in managing osteoarthritis.&#x000a0;</p>
      </sec>
      <sec id="article-35395.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Glucosamine sulfate may be taken in tablet or capsule form. Due to a lack of FDA approval, there is no validated effective dose.&#x000a0; However, glucosamine sulfate is typically taken as a 500 mg dose three times a day for those taking it as a desired osteoarthritis intervention.<xref ref-type="bibr" rid="article-35395.r14">[14]</xref></p>
      </sec>
      <sec id="article-35395.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Glucosamine has no serious adverse effects, but possible complications include <xref ref-type="bibr" rid="article-35395.r14">[14]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Epigastric pain</p>
          </list-item>
          <list-item>
            <p>Heartburn</p>
          </list-item>
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Nausea</p>
          </list-item>
        </list>
        <p>There have been no proven drug interactions. There was previously a theory that glucosamine sulfate might interfere with the effectiveness of diabetes medications; however, research has since refuted this concept.<xref ref-type="bibr" rid="article-35395.r10">[10]</xref></p>
        <p>There was also a report of one case study that glucosamine sulfate appeared to&#x000a0;exert some effect on the efficacy of warfarin when taken in combination; however, further studies are needed to validate this finding.</p>
      </sec>
      <sec id="article-35395.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The American Academy of Family Physicians lists patients with shellfish allergy, diagnosis of asthma, or use of diabetes medications or warfarin as &#x0201c;C&#x0201d; evidence contraindications (supported by consensus, disease-oriented evidence, usual practice, expert opinion, or case series). Although not prohibitive to glucosamine sulfate use, patients with one or more of these criteria should be monitored cautiously for potential adverse effects.<xref ref-type="bibr" rid="article-35395.r14">[14]</xref><xref ref-type="bibr" rid="article-35395.r15">[15]</xref><xref ref-type="bibr" rid="article-35395.r16">[16]</xref></p>
      </sec>
      <sec id="article-35395.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Prescribers should initially start patients on a closely monitored 60-day trial to ensure tolerability and screen for adverse side effects. For pharmacologically treated diabetic patients wishing to start glucosamine sulfate supplementation, the Arthritis Foundation recommends an increase in the frequency of blood glucose monitoring due to the theoretical risk of hyperglycemia.<xref ref-type="bibr" rid="article-35395.r14">[14]</xref></p>
      </sec>
      <sec id="article-35395.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Through various studies, Glucosamine sulfate has consistently been concluded to be a relatively safe oral supplement. A few isolated case studies have reported on the incidence of hepatotoxicity following &#x0003e;3 weeks of glucosamine sulfate use. However, all patients cited had severe preexisting liver disease, with one of the eight patients mentioned developing hepatic failure.<xref ref-type="bibr" rid="article-35395.r17">[17]</xref></p>
      </sec>
      <sec id="article-35395.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The evidence available on the effectiveness of glucosamine sulfate as a beneficial therapy in the management of osteoarthritis is, to date, inconclusive. Interestingly, studies have shown that patients are not deterred from supplement use when presented with data concluding lack of efficacy, with the only evidence of significant toxicity showing to be capable of causing changes in supplement consumption. Physicians should be mindful of this when discussing the benefits and risks of various treatment modalities with OA patients, particularly those of no validated benefit. The physician must personalize the risk and benefits of taking glucosamine sulfate to each patient. Typically, a 60-day trial of glucosamine sulfate will determine if there are beneficial effects, after which it should be discontinued if the patient has not observed any beneficial effect by that time.</p>
        <p>As patients search online for alternatives to medication,&#x000a0;clinicians must stay educated on various supplements a patient may seek out for their condition. Communication between all interprofessional healthcare team members, including pharmacists, is crucial in these situations. A pharmacist will know how different drugs and supplements could interact with a patient's current medications. Through collaborative effort and open communication between clinicians, nurses, and pharmacists, patients can integrate glucosamine supplements into their OA treatment regimen more safely and avoid adverse effects. [Level 5]</p>
      </sec>
      <sec id="article-35395.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=35395&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=35395">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/35395/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=35395">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-35395.s11">
        <title>References</title>
        <ref id="article-35395.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelson</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Osteoarthritis year in review 2017: clinical.</article-title>
            <source>Osteoarthritis Cartilage</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>319</fpage>
            <page-range>319-325</page-range>
            <pub-id pub-id-type="pmid">29229563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35395.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Deshpande</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Losina</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review.</article-title>
            <source>Osteoarthritis Cartilage</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>6</issue>
            <fpage>962</fpage>
            <page-range>962-72</page-range>
            <pub-id pub-id-type="pmid">26844640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35395.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henroitin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Reginster</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>In-vitro differences among nonsteroidal antiinflammatory drugs in their activities related to osteoarthritis pathophysiology.</article-title>
            <source>Osteoarthritis Cartilage</source>
            <year>1999</year>
            <month>May</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>355</fpage>
            <page-range>355-7</page-range>
            <pub-id pub-id-type="pmid">10329331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35395.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reichenbach</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sterchi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Scherer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trelle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>B&#x000fc;rgi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>B&#x000fc;rgi</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Dieppe</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>J&#x000fc;ni</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis: chondroitin for osteoarthritis of the knee or hip.</article-title>
            <source>Ann Intern Med</source>
            <year>2007</year>
            <month>Apr</month>
            <day>17</day>
            <volume>146</volume>
            <issue>8</issue>
            <fpage>580</fpage>
            <page-range>580-90</page-range>
            <pub-id pub-id-type="pmid">17438317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35395.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vlad</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>LaValley</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>McAlindon</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Felson</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <article-title>Glucosamine for pain in osteoarthritis: why do trial results differ?</article-title>
            <source>Arthritis Rheum</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>56</volume>
            <issue>7</issue>
            <fpage>2267</fpage>
            <page-range>2267-77</page-range>
            <pub-id pub-id-type="pmid">17599746</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35395.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Sang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta-analysis of randomized controlled trials.</article-title>
            <source>J Orthop Surg Res</source>
            <year>2018</year>
            <month>Jul</month>
            <day>06</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>170</fpage>
            <pub-id pub-id-type="pmid">29980200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35395.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richmond</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Irrgang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Marx</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Snyder-Mackler</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Watters</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Haralson</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Turkelson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Wies</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>St Andre</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sluka</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McGowan</surname>
                <given-names>R</given-names>
              </name>
              <collab>American Academy of Orthopaedic Surgeons</collab>
            </person-group>
            <article-title>Treatment of osteoarthritis of the knee (nonarthroplasty).</article-title>
            <source>J Am Acad Orthop Surg</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>591</fpage>
            <page-range>591-600</page-range>
            <pub-id pub-id-type="pmid">19726743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35395.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kantor</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Lampe</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Milne</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Associations between glucosamine and chondroitin supplement use and biomarkers of systemic inflammation.</article-title>
            <source>J Altern Complement Med</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>479</fpage>
            <page-range>479-85</page-range>
            <pub-id pub-id-type="pmid">24738579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35395.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meulyzer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vachon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Beaudry</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vinardell</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Richard</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Beauchamp</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Laverty</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride.</article-title>
            <source>Osteoarthritis Cartilage</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>973</fpage>
            <page-range>973-9</page-range>
            <pub-id pub-id-type="pmid">18295513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35395.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henrotin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mobasheri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marty</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis?</article-title>
            <source>Arthritis Res Ther</source>
            <year>2012</year>
            <month>Jan</month>
            <day>30</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>201</fpage>
            <pub-id pub-id-type="pmid">22293240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35395.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoshimura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sakamoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsuruta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ishida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nagaoka</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of the effect of glucosamine administration on biomarkers for cartilage and bone metabolism in soccer players.</article-title>
            <source>Int J Mol Med</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>487</fpage>
            <page-range>487-94</page-range>
            <pub-id pub-id-type="pmid">19724889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35395.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henrotin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chevalier</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Herrero-Beaumont</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>McAlindon</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mobasheri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pavelka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;n</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Weinans</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Biesalski</surname>
                <given-names>H</given-names>
              </name>
              <collab>Participants at the Hohenheim Consensus Conference in August 29th 2011</collab>
            </person-group>
            <article-title>Physiological effects of oral glucosamine on joint health: current status and consensus on future research priorities.</article-title>
            <source>BMC Res Notes</source>
            <year>2013</year>
            <month>Mar</month>
            <day>26</day>
            <volume>6</volume>
            <fpage>115</fpage>
            <pub-id pub-id-type="pmid">23531101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35395.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldring</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Otero</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Inflammation in osteoarthritis.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>471</fpage>
            <page-range>471-8</page-range>
            <pub-id pub-id-type="pmid">21788902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35395.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dahmer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schiller</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Glucosamine.</article-title>
            <source>Am Fam Physician</source>
            <year>2008</year>
            <month>Aug</month>
            <day>15</day>
            <volume>78</volume>
            <issue>4</issue>
            <fpage>471</fpage>
            <page-range>471-6</page-range>
            <pub-id pub-id-type="pmid">18756654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35395.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knudsen</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Sokol</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database.</article-title>
            <source>Pharmacotherapy</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>540</fpage>
            <page-range>540-8</page-range>
            <pub-id pub-id-type="pmid">18363538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35395.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gray</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Hutcheson</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Slavin</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Is glucosamine safe in patients with seafood allergy?</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>114</volume>
            <issue>2</issue>
            <fpage>459</fpage>
            <page-range>459-60</page-range>
            <pub-id pub-id-type="pmid">15341031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35395.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cerda</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bruguera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Par&#x000e9;s</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Hepatotoxicity associated with glucosamine and chondroitin sulfate in patients with chronic liver disease.</article-title>
            <source>World J Gastroenterol</source>
            <year>2013</year>
            <month>Aug</month>
            <day>28</day>
            <volume>19</volume>
            <issue>32</issue>
            <fpage>5381</fpage>
            <page-range>5381-4</page-range>
            <pub-id pub-id-type="pmid">23983444</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
